drugset / Trial / NCT03437265

A Pharmacokinetic Study of PLENVU® in Healthy Subjects

NCT03437265

Phase 1 Completed 19 enrolled Norgine Quotient Sciences · collab
NaSingle-groupOpen-labelTreatment

Summary

This study characterises the pharmacokinetic (PK) profile of the active ingredients of PLENVU (NER1006) and their related substances/metabolites. Subjects will receive PLENVU.

Timeline

Start
2020-09-03
Primary completion
2020-10-05
Completion
2020-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Plenvu Unknown 101.91 g Oral
Subject Plenvu Unknown 115.96 g Oral

Indications

No indication recorded.